Skip to main content
ADBIOTECH Co.,Ltd. logo

ADBIOTECH Co.,Ltd. - Investor Relations & Filings

Listed IPO Jan 2022
Ticker · 179530 ISIN · KR7179530001 KO Manufacturing
Open in API
Filings indexed 437 across all filing types
Latest filing 2026-07-03 Regulatory Filings
Country KR South Korea
Listing KO 179530 · 1 venue

About ADBIOTECH Co.,Ltd.

http://www.adbiotech.com

ADBIOTECH Co., Ltd. is a biotechnology company specializing in the development and commercialization of immune antibodies. The company's core competency is IgY (Immunoglobulin in Yolk) technology, which utilizes antibodies derived from eggs to create alternatives to conventional vaccines and antibiotics. Its product portfolio targets the livestock, aquaculture, and human health sectors, with applications for disease prevention and treatment in animals like salmon and shrimp, as well as human-focused developments for conditions related to Helicobacter pylori and cholesterol. The company manages the entire value chain from research and development to production and sales. ADBIOTECH is also expanding its technological capabilities into VHH (nanobody) technology, with a strategic focus on the global companion animal market.

Recent filings

Filing Released Lang Actions
주요사항보고서(타법인주식및출자증권양수결정)
Regulatory Filings Classification · 95% confidence The document is a 'Major Matter Report' (주요사항보고서) filed with the Korean financial authorities regarding the acquisition of shares in another company (타법인 주식 및 출자증권 양수결정). This type of filing is a mandatory regulatory disclosure for material corporate events, specifically M&A-related activities (acquisition of equity). While it involves M&A, it is a formal regulatory disclosure of a specific transaction rather than a general M&A announcement or a merger proposal document. Given the specific nature of the filing as a regulatory requirement for material events, it falls under the category of Regulatory Filings (RNS).
2026-07-03 Korean
합병등종료보고서(자산양수도)
M&A Activity Classification · 95% confidence The document is a 'Report on the Completion of Merger, etc. (Asset Acquisition)' filed with the Financial Supervisory Service (FSS) in Korea. It details the finalization of an asset acquisition (purchase of shares in Onhill by Adbiotech), including the transaction date, payment details, and the impact on the company's financial position. While it involves M&A-related activity, it is a formal regulatory filing confirming the completion of a previously announced transaction, which falls under the 'M&A Activity' (TAR) category for corporate filings regarding mergers and acquisitions.
2026-07-03 Korean
[기재정정]주요사항보고서(자기전환사채매도결정)
Capital/Financing Update Classification · 95% confidence The document is a formal regulatory filing titled 'Major Report (Decision to Sell Own Convertible Bonds)' with a 'Correction' (기재정정) header. It details the amendment of a previously submitted report regarding the sale of convertible bonds, specifically updating the payment receipt date. This falls under the category of capital structure changes and financing activities, which is classified as CAP (Capital/Financing Update).
2026-07-03 Korean
[기재정정]주요사항보고서(전환사채권발행결정)
Capital/Financing Update Classification · 100% confidence The document is a formal regulatory filing titled '[기재정정]주요사항보고서(전환사채권발행결정)', which translates to '[Correction] Major Report (Decision on Issuance of Convertible Bonds)'. It details amendments to the terms of a previously announced convertible bond issuance, including changes to maturity dates, conversion prices, and payment schedules. This falls under the category of capital and financing updates as it pertains to the company's debt structure and financing activities.
2026-06-26 Korean
주요사항보고서(전환사채권발행결정)
Capital/Financing Update Classification · 100% confidence The document is a 'Major Matters Report' (주요사항보고서) from a South Korean company (AdBiotech) detailing the decision to issue convertible bonds (전환사채권발행결정). This type of filing is a regulatory requirement for capital structure changes and financing activities. It provides specific details on the bond terms, conversion price, and use of proceeds, which falls under the 'Capital/Financing Update' category.
2026-06-26 Korean
주주총회소집결의 (임시주주총회)
Regulatory Filings Classification · 95% confidence The document is a formal notice of an upcoming Extraordinary General Meeting (EGM) for the company '애드바이오텍'. It provides the date, time, location, and the fact that the agenda items are yet to be finalized. Since this is a notification of a meeting rather than the actual presentation materials (AGM-R) or the results of the vote (DVA), and it serves as a regulatory announcement regarding corporate governance events, it falls under the category of Regulatory Filings (RNS).
2026-06-26 Korean

Browse filings by year

8 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.